Fig 3. Adjusted mean expenditures in the 3 months after diagnosis among age groups in lung cancer patients with metastases diagnosed in 2009 in Germany.

All-cause and lung cancer-specific total, inpatient, outpatient, and medication expenditures within the 3 months after diagnosis reported as recycled predictions with 95% confidence intervals. Significance levels (* <0.05, ** <0.01, *** < 0.0001) indicate significant differences between the age groups “young-old” (65–74 years), “middle-old” (75–84 years), and “old-old” (≥ 85 years) and the reference group “non-elderly” (≤ 65 years). Lung cancer-specific expenditures relate to inpatient visits with a primary diagnosis of lung cancer, medications used in antineoplastic therapy or as supportive drugs (e.g., antiemetics, antianemics), and outpatient cases with a diagnosis of lung cancer.